#9299 on the rich list of 14,644 insiders
David Bredt
Chief Scientific Officer at Rapport Therapeutics. Based in Boston, Massachusetts.
$9.3M
in disclosed stock, +$75K (+0.81%) today
Market closed. Prices as of Nov 19, 4:00 PM ET
- Rank
- 9299th of 14,644
- Companies held
- 1
- Largest holding
- RAPP, 100.0% of total
- Latest SEC filing
- Feb 19, 2026
What the $9.3M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP Common Stock | Directly | 393,075 | $23.59 | $9.3M | 100.0% | Form 4, Feb 19, 2026 |
Share counts are the amounts David Bredt reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | Sold | RAPP | 2,200 | $29.59 | $65K | View |
| Feb 17, 2026 | Sold | RAPP | 5,400 | $28.95 | $156K | View |
| Feb 17, 2026 | Sold | RAPP | 900 | $28.02 | $25K | View |
| Jan 15, 2026 | Sold | RAPP | 8,300 | $26.83 | $223K | View |
| Jan 15, 2026 | Sold | RAPP | 200 | $27.40 | $5K | View |
| Dec 31, 2025 | Sold | RAPP | 6,567 | $30.05 | $197K | View |
| Dec 15, 2025 | Sold | RAPP | 7,704 | $29.95 | $231K | View |
| Dec 15, 2025 | Sold | RAPP | 796 | $30.68 | $24K | View |
| Nov 17, 2025 | Sold | RAPP | 5,344 | $25.39 | $136K | View |
| Nov 17, 2025 | Sold | RAPP | 3,156 | $24.84 | $78K | View |
| Oct 15, 2025 | Sold | RAPP | 1,082 | $26.16 | $28K | View |
| Oct 15, 2025 | Sold | RAPP | 7,418 | $25.73 | $191K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 9296 | Patricia Hemingway Hall Director, Cardinal Health. Dublin, OH | $9.3M |
| 9297 | Fred Hassan Director, Precigen. Salt Lake City, UT | $9.3M |
| 9298 | Paul W. Jorgensen Chief Revenue Officer, Doximity. San Francisco, CA | $9.3M |
| 9299 | David Bredt Chief Scientific Officer, Rapport Therapeutics. Boston, MA | $9.3M |
| 9300 | Glenn H. Nussdorf Director, Organogenesis Holdings. Bellport, NY | $9.3M |
| 9301 | Robert J. Chersi Director, Acadian Asset Management | $9.3M |
| 9302 | John J. Abularrage Co-Chief Executive Officer, BGC Group. New York, NY | $9.3M |
Other Rapport Therapeutics insiders
All RAPP insiders- Steven M. Paul$13.1MDirector. #3878 overall
- Abraham Ceesay$13.0MChief Executive Officer. #6746 overall
- John Maraganore$222KDirector. #1984 overall
Questions
How much stock does David Bredt own?
David Bredt holds $9,272,639 in listed stock based on SEC filings and current prices, mostly Rapport Therapeutics (RAPP). That ranks 9299th on the Stock Rich List.
Is this David Bredt's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did David Bredt last buy or sell stock?
The most recent open-market trade on file is a sale of 2,200 RAPP shares on Feb 17, 2026 at $29.59.